<!-- @page { size: 21cm 29.7cm; margin: 2cm } P { margin-bottom: 0.21cm } -->
Descriptions of molluscum contagiosum have been in the medical literature since 1817. In 1905, the viral nature of molluscum contagiosum was discovered by Juliusburg. Molluscum contagiosum is a cutaneous infection caused by a large DNA poxvirus that affects both children and adults. It can likely be vertically transmitted, similarly to other viruses such as condyloma acuminatum and human papilloma virus (HPV).
Transmission of molluscum contagiosum has been reported by direct skin contact and has occurred in wrestlers, patients of a surgeon with a hand lesion, and children sharing baths, towels, gymnasium equipment, and benches. Autoinoculation also occurs as evidenced by linear arrays of lesions on infected individuals.
The virus that causes molluscum contagiosum replicates in the cytoplasm of epithelial cells producing cytoplasmic inclusions, and it may cause enlargement of infected cells. Reported data for 1966-1983 by the National Disease and Therapeutic Index Survey, which compiles information about patterns of disease in office-based practices in the continental United States, showed an increase in the number of patient visits for molluscum contagiosum.
Based on National Ambulatory Medical Care Survey data, an estimated 22 visits per 10,000 persons occurred among the general US population from 2001-2005. A population-based estimate of molluscum contagiosum-associated outpatient visits among American Indian/Alaskan natives from 2001-2005 was 20.15 annual outpatient visits per 10,000 American Indian/Alaskan native persons, with the highest incidence among children under age 15 years.
Molluscum contagiosum is more common in patients who are on steroid therapy or in those who have atopic dermatitis, immunodeficiency, or lymphoproliferative disorders. A molluscum contagiosum infection rate of 8% was seen in one study of 528 HIV-positive patients. The severity of molluscum contagiosum is inversely related to the CD4 T-lymphocyte count.
Molluscum contagiosum has been reported in 5.6% of children in kindergarten and in 7.4% of elementary school children. Molluscum contagiosum is common in the tropics and subtropics, probably because of the increased desquamation associated with hydration. Childhood molluscum contagiosum is common in Papua New Guinea, Fiji, and certain parts of Africa.
Epidemiological studies suggest that transmission may be related to poor hygiene and climatic factors, such as warmth and humidity. Persons of any race can be affected by molluscum contagiosum. Molluscum contagiosum affects both sexes equally. Molluscum contagiosum appears to have a bimodal age distribution.
The first is in childhood, when transmission occurs from nonsexual skin contact. The second is in early adulthood, when molluscum contagiosum occurs as a sexually transmitted disease. Although molluscum contagiosum can occur in persons of any age, population surveys conducted in Papua New Guinea and Fiji have found that the peak incidence of the disease is among children younger than 5 years, with a prevalence of approximately 25%.
AntiMolluscum-Rx is composed of naturally occurring high intensity antiviral extracts which have a lethal effect against the virus upon exposure. Application of this molluscum contagiosum treatment provides maximum and rapid penetration of antiviral agents into cell membranes without damaging healthy skin tissue.
As a result, this treatment for molluscum enjoys a well earned reputation for its curative effects. AntiMolluscum-Rx is the most effective among the organic molluscum treatments today as it has very strong and real antiviral properties that destroy the virus. The antiviral pharmacological activity of this molluscum treatment is well documented.
Molluscum occurring anywhere on the body can be successfully eliminated with application of AntiMolluscum-Rx. This product is concentrated with naturally occurring monoterpene aldehydes which have tremendous antiviral effects against the molluscum virus, as demonstrated in published scientific studies.
The mode of action of AntiMolluscum-Rx as a molluscum treatment is particularly interesting, not only in consideration of its ability to destroy the extra cellular molluscum virus in very small quantities, but also for its ability to stop the cell-to-cell virus proliferation. To learn more, please go to http://www.naturespharma.org.
Descriptions of molluscum contagiosum have been in the medical literature since 1817. In 1905, the viral nature of molluscum contagiosum was discovered by Juliusburg. Molluscum contagiosum is a cutaneous infection caused by a large DNA poxvirus that affects both children and adults. It can likely be vertically transmitted, similarly to other viruses such as condyloma acuminatum and human papilloma virus (HPV).
Transmission of molluscum contagiosum has been reported by direct skin contact and has occurred in wrestlers, patients of a surgeon with a hand lesion, and children sharing baths, towels, gymnasium equipment, and benches. Autoinoculation also occurs as evidenced by linear arrays of lesions on infected individuals.
The virus that causes molluscum contagiosum replicates in the cytoplasm of epithelial cells producing cytoplasmic inclusions, and it may cause enlargement of infected cells. Reported data for 1966-1983 by the National Disease and Therapeutic Index Survey, which compiles information about patterns of disease in office-based practices in the continental United States, showed an increase in the number of patient visits for molluscum contagiosum.
Based on National Ambulatory Medical Care Survey data, an estimated 22 visits per 10,000 persons occurred among the general US population from 2001-2005. A population-based estimate of molluscum contagiosum-associated outpatient visits among American Indian/Alaskan natives from 2001-2005 was 20.15 annual outpatient visits per 10,000 American Indian/Alaskan native persons, with the highest incidence among children under age 15 years.
Molluscum contagiosum is more common in patients who are on steroid therapy or in those who have atopic dermatitis, immunodeficiency, or lymphoproliferative disorders. A molluscum contagiosum infection rate of 8% was seen in one study of 528 HIV-positive patients. The severity of molluscum contagiosum is inversely related to the CD4 T-lymphocyte count.
Molluscum contagiosum has been reported in 5.6% of children in kindergarten and in 7.4% of elementary school children. Molluscum contagiosum is common in the tropics and subtropics, probably because of the increased desquamation associated with hydration. Childhood molluscum contagiosum is common in Papua New Guinea, Fiji, and certain parts of Africa.
Epidemiological studies suggest that transmission may be related to poor hygiene and climatic factors, such as warmth and humidity. Persons of any race can be affected by molluscum contagiosum. Molluscum contagiosum affects both sexes equally. Molluscum contagiosum appears to have a bimodal age distribution.
The first is in childhood, when transmission occurs from nonsexual skin contact. The second is in early adulthood, when molluscum contagiosum occurs as a sexually transmitted disease. Although molluscum contagiosum can occur in persons of any age, population surveys conducted in Papua New Guinea and Fiji have found that the peak incidence of the disease is among children younger than 5 years, with a prevalence of approximately 25%.
AntiMolluscum-Rx is composed of naturally occurring high intensity antiviral extracts which have a lethal effect against the virus upon exposure. Application of this molluscum contagiosum treatment provides maximum and rapid penetration of antiviral agents into cell membranes without damaging healthy skin tissue.
As a result, this treatment for molluscum enjoys a well earned reputation for its curative effects. AntiMolluscum-Rx is the most effective among the organic molluscum treatments today as it has very strong and real antiviral properties that destroy the virus. The antiviral pharmacological activity of this molluscum treatment is well documented.
Molluscum occurring anywhere on the body can be successfully eliminated with application of AntiMolluscum-Rx. This product is concentrated with naturally occurring monoterpene aldehydes which have tremendous antiviral effects against the molluscum virus, as demonstrated in published scientific studies.
The mode of action of AntiMolluscum-Rx as a molluscum treatment is particularly interesting, not only in consideration of its ability to destroy the extra cellular molluscum virus in very small quantities, but also for its ability to stop the cell-to-cell virus proliferation. To learn more, please go to http://www.naturespharma.org.
Source...